Clinical trials: Chronic Obstructive Pulmonary
COPD Patients and Patients Recovering From COVID19
Increasing Physical Activity in COPD Through Rhythmically Enhanced Music
The VA cares for nearly one million Veterans with COPD at a cost of more than $5.5 billion annually. COPD profoundly impairs quality of life as it limits ability to work, to maintain physical exertion and to engage in social…
- Trial name
- NCT03655028
- Testing
- rhythmically auditory stimulation enhanced music, control
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development
Pulmonary Disease, Chronic Obstructive
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
The objective of this study is to demonstrate that, when added to tiotropium (TIO), fluticasone propionate/salmeterol combination (FSC) DISKUS 250/50 significantly increases exercise endurance time (EET) in the endurance shuttle…
- Trial name
- ESWT (NCT01124422)
- Testing
- fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
- Where
- 27 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- GlaxoSmithKline
Asthma Chronic
Azithromycin Treatment for the Airway Microbiome in Asthma
The purpose of this study to determine whether the bacteria inside the lungs of people with asthma can be modified (changed) if they are given an antibiotic and if this change is associated with an improvement in asthma symptoms.
- Trial name
- NCT03736629
- Testing
- Azithromycin
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Pulmonary Disease, Chronic Obstructive
Ventilator Adapters for Combivent Respimat
The general aim of this 1-day, open label, non-randomised, trial is to characterize the performance of two adapter devices designed to permit use of the Respimat® inhaler with patients requiring mechanical ventilation.
- Trial name
- NCT01969539
- Testing
- Combivent Respimat via tee adapter, Combivent Respimat via ventilator adapter
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Effect of Oxygen-supply on 6-Minute-Walking-Distance of COPD III/IV-patients
The aim of this study is to investigate the six-minute-walking-distance of COPD-patients with breathing oxygen in comparison to breathing normal air.
- Trial name
- NCT00886639
- Testing
- 6MWT with oxygen, 6MWT with medical air
- Where
- Germany
- Volunteers
- 127 people
- Sponsor
- Schön Klinik Berchtesgadener Land
COPD, Chronic Obstructive Pulmonary Disease
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the dose-response of different doses of CHF 5259 pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development…
- Trial name
- GLIMMER (NCT03084796)
- Testing
- CHF 5259, Tiotropium Bromide 18 µg Inhalation Capsule
- Where
- 112 sites in United States
- Volunteers
- 733 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Capnometry-Assisted Breathing Training for COPD
Capnometry-Assisted Breathing Training for COPD (CATCH) is a behavioral intervention that aims to promote optimal, self-regulated, mindful breathing.
- Trial name
- CATCH (NCT03457103)
- Testing
- Capnometry-Assisted Training for COPD to Slow the Breath (CATCH), Pulmonary Rehabilitation (PR)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- NYU Langone Health
Pulmonary Disease, Chronic Obstructive
HHHFA in COPD Patients, With Chronic Bronchitis
Heated, humidified high-flow air (HHHFA) devices improve airway clearance. HHHFA use for an average of 1.6 hours a day in COPD patients with chronic bronchitis improves health-related quality of life, lung function, and delays…
- Trial name
- NCT03959982
- Testing
- HHHFA Device, Spirometry, 6-minute walk
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Spyridon Fortis
Pulmonary Disease, Chronic Obstructive
Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities
The objective of the present Post Marketing Surveillance Study (PMS) study is to evaluate safety and effectiveness of tiotropium bromide (Spiriva®) 18 µg once daily in 5,000 patients with COPD of varying severities over 8 weeks.
- Trial name
- NCT00621582
- Volunteers
- 4,918 people
- Sponsor
- Boehringer Ingelheim
Alpha-1 Antitrypsin Deficiency, Emphysema
Alpha-1 Carrier Genomics Study
The goal of this study is to better understand why some Alpha-1 genotype MZ (PiMZ) individuals develop chronic obstructive pulmonary disease (COPD) while others do not.
- Conditions
- Alpha-1 Antitrypsin Deficiency, Emphysema, COPD, Smoking
- Trial name
- NCT02810327
- Testing
- Genetic Sequencing
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Medical University of South Carolina
COPD, Chronic Bronchitis
N-Acetylcysteine for Patients With COPD and Chronic Bronchitis
N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is widely prescribed for patients with chronic obstructive lung disease (COPD), particularly for those who have accompanying symptoms of…
- Trial name
- NCT01739790
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Minnesota
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in…
- Trial name
- NCT01572792
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate
- Where
- 208 sites in United States, Australia and 2 more
- Volunteers
- 921 people
- Sponsor
- AstraZeneca
COPD, Bronchiectasis
COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2
Patients with a respiratory disease are at higher risk of poor outcomes due to worsening of symptoms caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and other respiratory infections.
- Trial name
- CORVIS (NCT04858451)
- Testing
- RESP301
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- Thirty Respiratory Limited
Pulmonary Disease, Chronic Obstructive
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
Subjects who have not used the ELLIPTA™ inhaler nor the DISKUS™ inhaler in the past 6 months will be screened to participate in the study.
- Trial name
- NCT01868009
- Testing
- ELLIPTA, DISKUS
- Where
- 17 sites in United States
- Volunteers
- 287 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease COPD
A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy
The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.
- Trial name
- NCT02238483
- Testing
- AZD7624 1.0 mg
- Where
- 41 sites in United States, Argentina and 4 more
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change
This study evaluates hospitalizations and mortality in patients with Chronic Obstructive Pulmonary Disease (COPD) before and after the implantation of a new COPD treatment plan (replacement of tiotropium soft mist inhaler for…
- Trial name
- NCT06053541
- Where
- Brazil
- Volunteers
- 3,015,000 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
IVR-Enhanced Care Transition Support for Complex Patients
For complex medical patients, the transition from hospital to home-based care is a vulnerable period, placing the patient at high risk for adverse events.
- Trial name
- NCT01135381
- Testing
- IVR-Enhanced Care
- Where
- United States
- Volunteers
- 511 people
- Sponsor
- University of Alabama at Birmingham
Pulmonary Disease, Chronic Obstructive
Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
The purpose of this study is to evaluate the efficacy and safety of the FSC HFA MDI in subjects with COPD. The dose of FSC HFA MDI to be evaluated corresponds to the dose of FSC DISKUS (250/50mcg twice-daily) that is indicated…
- Trial name
- NCT00633217
- Testing
- Fluticasone Propionate/Salmeterol DISKUS 250/50mcg, Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
- Where
- 16 sites in United States
- Volunteers
- 247 people
- Sponsor
- GlaxoSmithKline
Asthma, COPD
The Natural History of Small Airways Physiology in Diseased and Healthy States
Spirometry is a useful clinical tool for the assessment and monitoring of lung disease, however, it does not provide information on peripheral airways resistance.
- Conditions
- Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis
- Trial name
- NCT00677560
- Where
- United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Imperial College London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.